-
Tytuł:
-
Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France.
-
Autorzy:
-
Potard V; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Gallien S; AP-HP, Hôpital Henri Mondor, Service d'Immunologie et Maladies Infectieuses, Université Paris Est Créteil, Inserm U 955, Créteil, France.
Canestri A; AP-HP, Hôpital de Tenon, Service des Maladies Infectieuses et Tropicales, Paris, France.
Costagliola D; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
-
Corporate Authors:
-
French Hospital Database on HIV (FHDH-ANRS CO4)
-
Źródło:
-
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2021 Jan 19; Vol. 76 (2), pp. 467-476.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 1997- : London : Oxford University Press
Original Publication: London, New York, Academic Press.
-
MeSH Terms:
-
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV-1*
Sexual and Gender Minorities*
France/epidemiology ; Homosexuality, Male ; Humans ; Male ; Rilpivirine/therapeutic use ; Viral Load
-
Contributed Indexing:
-
Investigator: S Abel; S Abgrall; C Allavena; H Bazus; A Becker; B François; P Bouvet De La Maisonneuve; S Bregigeon; A Brugnon; F Caby; R Calin; A Cheret; D Costagliola; P Truchis; B Denis; C Duvivier; P Enel; H Fischer; J Ghosn; M Goussef; S Grabar; F Huber; C Jacomet; V Joly; C Katlama; MA Khuong; A Makinson; L Marchand; G Martin-Blondel; S Matheron; JL Meynard; P Miailhes; M Nacher; E Piet; L Piroth; M Ploquin; V Rabier; O Robineau; E Rouveix Nordon; P Tattevin
-
Substance Nomenclature:
-
0 (Anti-HIV Agents)
FI96A8X663 (Rilpivirine)
-
Entry Date(s):
-
Date Created: 20201201 Date Completed: 20210630 Latest Revision: 20210630
-
Update Code:
-
20240105
-
DOI:
-
10.1093/jac/dkaa449
-
PMID:
-
33257955
-
Objectives: We assessed virological outcomes of rilpivirine use in France from 2012 to 2017, in three groups of people living with HIV (PLHIV): (i) antiretroviral (ARV)-naive PLHIV; (ii) ARV-experienced PLHIV switching to rilpivirine while failing therapy; and (iii) ARV-experienced PLHIV switching to rilpivirine while virologically controlled.
Methods: Virological success (VS) was defined as a plasma HIV-1 viral load (VL) <50 copies/mL and virological failure (VF) as two consecutive VL >50 copies/mL or one VL >50 copies/mL followed by a treatment switch prior to the next VL measurement. The cumulative incidence of VS was assessed considering rilpivirine discontinuation, loss to follow-up and death as competing risks, while estimates of cumulative incidence of VF accounted for loss to follow-up and death.
Results: Among the 2166 ARV-naive PLHIV initiating rilpivirine, the 4 year cumulative incidence of VS was 91.0% and was associated with baseline VL. Among the 2125 ARV-experienced PLHIV switching to rilpivirine while failing therapy, the 4 year cumulative incidence of VS was 82.5% and was associated with lower VL, higher CD4 and less than three prior ARVs. Among the 11 828 ARV-experienced PLHIV switching to rilpivirine while virologically controlled, the 4 year cumulative incidence of VF was 9.6%. The risk of VF was lower among MSM, for PLHIV with CD4 ≥ 500 cell/mm3, without a prior AIDS event, or with a longer VL suppression at baseline.
Conclusions: Rilpivirine-containing regimens yielded high rates of viral suppression in most participants, while it was ineffective when used outside the marketing authorization in naive participants.
(© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
